SEC 13F Intelligence

Managers / Q3 2024 · view latest →

Checkpoint Capital L.P.

CIK 0001977548 · 345 CALIFORNIA STREET, SUITE 600, SAN FRANCISCO, CA, 94104 · 914-355-0570

Reported Value
$202M
Q3 2024
Positions
16
Filings on Record
10
2019–present window
Filed
Nov 14, 2024
original filing

Summary

Checkpoint Capital L.P. reported $202M in U.S.-listed holdings across 16 positions for Q3 2024.

The portfolio is heavily concentrated: ARGX alone accounts for 24.9% of reported value.

Compared with Q2 2024, the fund opened 3 new positions and exited 3.

Portfolio Metrics

Turnover
+12.6%
vs prior filed quarter
Top-10 Concentration
+95.4%
share of reported value
Largest Position
+24.9%
Argenx
New / Exited
3 / 3
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’23: $165MQ4 ’23Q1 ’24: $150MQ2 ’24: $166MQ2 ’24Q3 ’24: $202MQ4 ’24: $196MQ4 ’24Q1 ’25: $182MQ2 ’25: $215MQ2 ’25Q3 ’25: $298MQ4 ’25: $320MQ4 ’25Q1 ’26: $279Mfilingsflow.com

Portfolio Composition

By security type
Common Stock: 68.0%ADR: 24.9%Other: 7.2%
  • Common Stock · 68.0% · $137M
  • ADR · 24.9% · $50M
  • Other · 7.2% · $14M

Quarter-over-Quarter Changes full breakdown →

vs Q2 2024 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
TCRXTSCAN THERAPEUTICS INCNEW+825.3K825.3K+$4M$4M
STOKSTOKE THERAPEUTICS INCNEW+157.5K157.5K+$2M$2M
IRONDISC MEDICINE INCNEW+25.5K25.5K+$1M$1M
SOLENO THERAPEUTICS INCADDED+38.3K58.0K+$2M$3M
CYTKCYTOKINETICS INCADDED+276.8K466.8K+$14M$25M
CORTCORCEPT THERAPEUTICS INCSOLD OUT−244.8K0−$8M$0
KYMRKYMERA THERAPEUTICS INCSOLD OUT−82.0K0−$2M$0
APLTAPPLIED THERAPEUTICS INCSOLD OUT−227.5K0−$1M$0

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q3 2024

16 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1ARGXARGENX SEhistory →SPONSORED ADR24.88%$50M92.5K
2RYTMRHYTHM PHARMACEUTICALS INChistory →COM17.24%$35M663.4K
3PHATPHATHOM PHARMACEUTICALS INChistory →COM13.49%$27M1.50M
4CYTKCYTOKINETICS INChistory →COM NEW12.23%$25M466.8K
5AXSMAXSOME THERAPEUTICS INChistory →COM9.35%$19M209.6K
6AVADEL PHARMACEUTICALS PLCCOM SHS7.16%$14M1.10M
7PTGXPROTAGONIST THERAPEUTICS INChistory →COM5.36%$11M240.0K
8PLRXPLIANT THERAPEUTICS INChistory →COM2.11%$4M380.0K
9TCRXTSCAN THERAPEUTICS INChistory →COM2.04%$4M825.3K
10ATYRATYR PHARMA INChistory →COM NEW1.52%$3M1.74M
11SOLENO THERAPEUTICS INCCOM1.45%$3M58.0K
12CDTXCIDARA THERAPEUTICS INCCOM NEW0.97%$2M182.4K
13STOKSTOKE THERAPEUTICS INCCOM0.96%$2M157.5K
14IRONDISC MEDICINE INCCOM0.62%$1M25.5K
15TRVITREVI THERAPEUTICS INCCOM0.41%$835,000250.0K
16ALLAKOS INCCOM0.21%$424,552650.0K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$279M8May 15, 202613F-HRchanges · EDGAR ↗
Q4 2025$320M7Feb 17, 202613F-HRchanges · EDGAR ↗
Q3 2025$298M10Nov 14, 202513F-HRchanges · EDGAR ↗
Q2 2025$215M8Aug 14, 202513F-HRchanges · EDGAR ↗
Q1 2025$182M14May 15, 202513F-HRchanges · EDGAR ↗
Q4 2024$196M16Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$202M16Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$166M16Aug 14, 202413F-HRchanges · EDGAR ↗
Q1 2024$150M17May 15, 202413F-HRchanges · EDGAR ↗
Q4 2023$165M19Feb 14, 202413F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.